HealthyNCT00680082
Observational Usage Study of Statins in Primary Care in France
An observational study of Healthy, run by AstraZeneca at 25 sites in China.
Trial summary
To describe the way statins are used in France in primary care, that is to determine patients profile (particularly CV risk factors), to determine the way statins are initiated by general practitioners, to evaluate aftercare and to assess patients treated by rosuvastatin Read more about this study
- Who is it for?
- Any ageHealthy volunteers can take part
- Conditions the study is for
- Healthy
- How many people
- 2,100 participants
- Where
- 25 sitesChina
- Study dates
- Feb 2008to Jul 2009
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Study population: Patients recruited by a GP, community sample
Who may be able to join
- Patients to whom a statin was initiated or switched between 3 and 6 months before consultation
Who cannot join
None listed.
Trial locations and contacts
25 sites in 1 country.
25 sites in 1 country
China25 sites
Research Site
Changsha, Hunan
Research Site
Chengdu, Sichuan
Research Site
Chongqing, Chongqing Municipality
Research Site
Fuzhou, Fujian
Research Site
Guangzhou, Guangdong
Research Site
Hangzhou, Zhejiang
Research Site
Hefei, Anhui
Research Site
Jinan, Shandong
Research Site
Kunming, Yunnan
Research Site
Nanchang, Jiangxi
Research Site
Nanjing, Jiangsu
Research Site
Ningbo, Zhejiang
Research Site
Qingdao, Shandong
Research Site
Rui’an, Zhejiang
Research Site
Shanghai, Shanghai Municipality
Research Site
Shenzhen, Guangdong
Research Site
Suzhou, Jiangsu
Research Site
Taiyuan, Shanxi
Research Site
Wenzhou, Zhejiang
Research Site
Wuhan, Hubei
Research Site
Wuxi, Jiangsu
Research Site
Xi’an, Shanxi
Research Site
Xiamen, Guangdong
Research Site
Zhengzhou, Henan
Research Site
Zhongshan, Guangdong
About this study
To describe the way statins are used in France in primary care, that is to determine patients profile (particularly CV risk factors), to determine the way statins are initiated by general practitioners, to evaluate aftercare and to assess patients treated by rosuvastatin
- Conditions
- Healthy
- Keywords
- statins, rosuvastatin, cross sectional study, France, CV risk factors
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| 1 | Patients to whom a statin was initiated or switched between 3 and 6 months before consultation |
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 May 2008 (estimated)
- Study startFeb 2008
- Primary completionJul 2009
- Study completionJul 2009
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HealthyStudies of the same condition, open and under way.
- More trials run by AstraZenecaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 2,100 participants (actual)
Sponsor and investigators
- Lead sponsor
- AstraZeneca
- Sponsor type
- Industry (pharma, biotech, devices)
- Investigators
- Francois Morand, Principal investigator, Cegedim Strategic Data - Boulogne Billancourt - FranceJean Dallongeville, Study chair, Institut Pasteur - Inserm U744 - Lille -France
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00680082
- Sponsor's protocol ID
- NIS-CFR-CRE-2007/2
- Status last verified
- Dec 2010
- First submitted
- 15 May 2008
- Last updated
- 2 Dec 2010
- Results posted
- No
- Data monitoring committee
- Yes